PubRank

Lucia Altucci

Author PubWeight™ 111.94‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol 2012 3.24
2 Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2004 2.72
3 Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2004 2.71
4 PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell 2010 2.50
5 Whole-genome bisulfite sequencing of two distinct interconvertible DNA methylomes of mouse embryonic stem cells. Cell Stem Cell 2013 2.32
6 Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov 2007 1.91
7 HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci U S A 2008 1.80
8 "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 2009 1.59
9 Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol Cell Biol 2004 1.56
10 Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J Med Chem 2005 1.51
11 Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep 2009 1.39
12 A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J Mol Endocrinol 2004 1.35
13 Retinoids: potential in cancer prevention and therapy. Expert Rev Mol Med 2004 1.25
14 Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 2008 1.21
15 A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood 2013 1.19
16 Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: evidence for HDAC2 involvement. Stem Cells 2014 1.19
17 Trials with 'epigenetic' drugs: an update. Mol Oncol 2012 1.19
18 Sirtuins and disease: the road ahead. Front Pharmacol 2012 1.15
19 epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors. J Med Chem 2008 1.13
20 ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood 2012 1.12
21 Molecular pathways involved in neural in vitro differentiation of marrow stromal stem cells. J Cell Biochem 2005 1.10
22 Nε-lysine acetylation determines dissociation from GAP junctions and lateralization of connexin 43 in normal and dystrophic heart. Proc Natl Acad Sci U S A 2011 1.09
23 Comparative genome-wide DNA methylation analysis of colorectal tumor and matched normal tissues. Epigenetics 2012 1.08
24 Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS One 2010 1.08
25 Bispyridinium dienes: histone deacetylase inhibitors with selective activities. J Med Chem 2007 1.08
26 Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res 2008 1.07
27 Molecular identification of ERalpha-positive breast cancer cells by the expression profile of an intrinsic set of estrogen regulated genes. J Cell Physiol 2004 1.06
28 Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia. Blood 2012 1.02
29 Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. J Med Chem 2006 1.02
30 HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochim Biophys Acta 2008 1.02
31 Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem 2006 0.98
32 HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. J Mol Endocrinol 2010 0.98
33 Synthesis and biological validation of novel synthetic histone/protein methyltransferase inhibitors. ChemMedChem 2007 0.97
34 Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors. J Med Chem 2009 0.97
35 Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia. Mol Pharmacol 2007 0.97
36 Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392. Cancer Res 2014 0.96
37 Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. J Med Chem 2012 0.96
38 Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues. J Med Chem 2010 0.96
39 Histone deacetylase inhibitors promote apoptosis and senescence in human mesenchymal stem cells. Stem Cells Dev 2009 0.95
40 Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells. Biochimie 2012 0.94
41 Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile. Bioorg Med Chem 2011 0.92
42 Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors. Mol Cancer Ther 2008 0.91
43 Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model. PLoS Curr 2010 0.91
44 Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. J Med Chem 2013 0.91
45 Histone acetyltransferase inhibitors and preclinical studies. Expert Opin Ther Pat 2009 0.90
46 Cannabinoid receptor 1 influences chromatin remodeling in mouse spermatids by affecting content of transition protein 2 mRNA and histone displacement. Endocrinology 2010 0.90
47 Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases. Bioorg Med Chem Lett 2008 0.89
48 Endocannabinoid control of sperm motility: the role of epididymus. Gen Comp Endocrinol 2007 0.89
49 Distinct signaling pathways mediate stimulation of cell cycle progression and prevention of apoptotic cell death by estrogen in rat pituitary tumor PR1 cells. Mol Biol Cell 2003 0.88
50 Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res 2006 0.88
51 Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor UVI5008. Mol Cancer Ther 2011 0.88
52 New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations. Int J Biochem Cell Biol 2008 0.87
53 Histone deacetylase inhibitors: recent insights from basic to clinical knowledge & patenting of anti-cancer actions. Recent Pat Anticancer Drug Discov 2011 0.87
54 Carbamate prodrug concept for hydroxamate HDAC inhibitors. ChemMedChem 2011 0.86
55 Identification of tri- and tetracyclic pyrimidinediones as sirtuin inhibitors. ChemMedChem 2010 0.86
56 A gradient of 2-arachidonoylglycerol regulates mouse epididymal sperm cell start-up. Biol Reprod 2009 0.86
57 Growth factor-antagonized rexinoid apoptosis involves permissive PPARgamma/RXR heterodimers to activate the intrinsic death pathway by NO. Cancer Cell 2009 0.85
58 Synthesis of benzamides related to anacardic acid and their histone acetyltransferase (HAT) inhibitory activities. ChemMedChem 2008 0.85
59 Regulation of interleukin-8 gene at a distinct site of its promoter by CCAAT enhancer-binding protein homologous protein in prostaglandin E2-treated human T cells. J Biol Chem 2008 0.85
60 Histone deacetylase inhibitors: a patent review (2009 - 2011). Expert Opin Ther Pat 2012 0.85
61 Low 17beta-estradiol levels in CNR1 knock-out mice affect spermatid chromatin remodeling by interfering with chromatin reorganization. Biol Reprod 2013 0.85
62 Molecular pathways: the complexity of the epigenome in cancer and recent clinical advances. Clin Cancer Res 2012 0.84
63 Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells. J Cell Physiol 2010 0.84
64 Feijoa sellowiana derived natural Flavone exerts anti-cancer action displaying HDAC inhibitory activities. Int J Biochem Cell Biol 2007 0.83
65 Identification of microRNA expression patterns in cutaneous and uveal melanoma cell lines. Tumori 2014 0.83
66 HDAC modulation and cell death in the clinic. Exp Cell Res 2012 0.83
67 Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors. J Med Chem 2006 0.83
68 1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells. J Med Chem 2014 0.82
69 Relationship between genome and epigenome--challenges and requirements for future research. BMC Genomics 2014 0.82
70 Nuclear size as estrogen-responsive chromatin quality parameter of mouse spermatozoa. Gen Comp Endocrinol 2013 0.82
71 Coexpression of Helicobacter pylori's proteins CagA and HspB induces cell proliferation in AGS gastric epithelial cells, independently from the bacterial infection. Cancer Res 2003 0.82
72 Laccase treatment impairs bisphenol A-induced cancer cell proliferation affecting estrogen receptor alpha-dependent rapid signals. IUBMB Life 2008 0.82
73 Epigenetic drugs against cancer: an evolving landscape. Arch Toxicol 2014 0.81
74 Altered folate receptor 2 expression in uraemic patients on haemodialysis: implications for folate resistance. Nephrol Dial Transplant 2013 0.81
75 Modulation of the activity of histone acetyltransferases by long chain alkylidenemalonates (LoCAMs). Bioorg Med Chem 2011 0.81
76 Antioxidant, antimicrobial and anti-proliferative activities of Solanum tuberosum L. var. Vitelotte. Food Chem Toxicol 2013 0.81
77 TNF-related apoptosis-inducing ligand: signalling of a 'smart' molecule. Int J Biochem Cell Biol 2007 0.81
78 Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability. J Transl Med 2008 0.81
79 MePR: a novel human mesenchymal progenitor model with characteristics of pluripotency. Stem Cells Dev 2013 0.81
80 Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol analogues. J Med Chem 2010 0.81
81 New anacardic acid-inspired benzamides: histone lysine acetyltransferase activators. ChemMedChem 2010 0.81
82 Epigenetic profiling of the antitumor natural product psammaplin A and its analogues. Bioorg Med Chem 2010 0.80
83 ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias. Epigenetics 2015 0.80
84 Benzodeazaoxaflavins as sirtuin inhibitors with antiproliferative properties in cancer stem cells. J Med Chem 2012 0.80
85 Novel pyrrole-containing histone deacetylase inhibitors endowed with cytodifferentiation activity. Int J Biochem Cell Biol 2007 0.80
86 Functions, aberrations, and advances for chromatin modulation in cancer. Cancer Treat Res 2014 0.80
87 Quinoline-based p300 histone acetyltransferase inhibitors with pro-apoptotic activity in human leukemia U937 cells. ChemMedChem 2014 0.80
88 Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases. Bioorg Med Chem Lett 2008 0.80
89 Indole-derived psammaplin A analogues as epigenetic modulators with multiple inhibitory activities. J Med Chem 2012 0.80
90 Highlighting chromosome loops in DNA-picked chromatin (DPC). Epigenetics 2011 0.79
91 New synthetic approach to paullones and characterization of their SIRT1 inhibitory activity. Org Biomol Chem 2012 0.79
92 Molecular analysis of the apoptotic effects of BPA in acute myeloid leukemia cells. J Transl Med 2009 0.79
93 Targeting epigenetic networks with polypharmacology: a new avenue to tackle cancer. Epigenomics 2010 0.79
94 The class I-specific HDAC inhibitor MS-275 modulates the differentiation potential of mouse embryonic stem cells. Biol Open 2013 0.78
95 Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group. Bioorg Med Chem Lett 2009 0.78
96 miRNA-mediated deregulation in leukemia. Front Genet 2012 0.78
97 Regulation of nuclear receptor and cofactor expression in breast cancer cell lines. Eur J Endocrinol 2003 0.78
98 tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells. ChemMedChem 2013 0.78
99 The Jumonji family: past, present and future of histone demethylases in cancer. Biomol Concepts 2014 0.78
100 SIRT1 inhibition affects angiogenic properties of human MSCs. Biomed Res Int 2014 0.77
101 Carprofen analogues as sirtuin inhibitors: enzyme and cellular studies. ChemMedChem 2012 0.77
102 TRAIL: at the center of drugable anti-tumor pathways. Cell Cycle 2005 0.77
103 Analysis of chromatin-nuclear receptor interactions by laser-chromatin immunoprecipitation. Methods Mol Biol 2014 0.77
104 Time for epigenetics. Int J Biochem Cell Biol 2008 0.76
105 Total synthesis of the proposed structures of the DNA methyl transferase inhibitors peyssonenynes, and structural revision of peyssonenyne B. Org Biomol Chem 2011 0.76
106 Synthetic approaches to DNMT inhibitor SGI-1027 and effects on the U937 leukemia cell line. Bioorg Med Chem Lett 2013 0.76
107 Histone deacetylase inhibitors: clinical implications for hematological malignancies. Clin Epigenetics 2010 0.76
108 Design, synthesis, and biological evaluation of 2-aminobenzanilide derivatives as potent and selective HDAC inhibitors. ChemMedChem 2012 0.76
109 Pyrrole-based hydroxamates and 2-aminoanilides: histone deacetylase inhibition and cellular activities. ChemMedChem 2009 0.76
110 Up-regulation of miR-146b and down-regulation of miR-200b contribute to the cytotoxic effect of histone deacetylase inhibitors on ras-transformed thyroid cells. J Clin Endocrinol Metab 2013 0.76
111 Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities. Bioorg Med Chem Lett 2008 0.76
112 Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia. Expert Opin Ther Targets 2015 0.75
113 Epigenetic multiple modulators. Curr Top Med Chem 2011 0.75
114 Cancer therapy: new drugs are emerging based on molecular targeting but still many challenges. Int J Biochem Cell Biol 2007 0.75
115 A DNA methyltransferase modulator inspired by peyssonenyne natural product structures. ChemMedChem 2012 0.75
116 Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents. Bioorg Med Chem 2008 0.75
117 Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: apoptotic induction and cytodifferentiation activity. ChemMedChem 2011 0.75